Pregnant women’s knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines

Vaccine ◽  
2019 ◽  
Vol 37 (44) ◽  
pp. 6743-6749 ◽  
Author(s):  
Michelle L Giles ◽  
Jim Buttery ◽  
Mary-Ann Davey ◽  
Euan Wallace
2017 ◽  
Vol 17 (7) ◽  
pp. e223-e234 ◽  
Author(s):  
Paul T Heath ◽  
Fiona J Culley ◽  
Christine E Jones ◽  
Beate Kampmann ◽  
Kirsty Le Doare ◽  
...  

2020 ◽  
Vol 225 ◽  
pp. 259-262
Author(s):  
Margaret S. Barton ◽  
Hillary Spencer ◽  
David P. Johnson ◽  
Travis W. Crook ◽  
Patricia A. Frost ◽  
...  

2001 ◽  
Vol 43 (3) ◽  
pp. 125-131 ◽  
Author(s):  
Sandra E. VIEIRA ◽  
Klaus E. STEWIEN ◽  
Divina A. O. QUEIROZ ◽  
Edison L. DURIGON ◽  
Thomas J. TÖRÖK ◽  
...  

The respiratory viruses are recognized as the most frequent lower respiratory tract pathogens for infants and young children in developed countries but less is known for developing populations. The authors conducted a prospective study to evaluate the occurrence, clinical patterns, and seasonal trends of viral infections among hospitalized children with lower respiratory tract disease (Group A). The presence of respiratory viruses in children's nasopharyngeal was assessed at admission in a pediatric ward. Cell cultures and immunofluorescence assays were used for viral identification. Complementary tests included blood and pleural cultures conducted for bacterial investigation. Clinical data and radiological exams were recorded at admission and throughout the hospitalization period. To better evaluate the results, a non- respiratory group of patients (Group B) was also constituted for comparison. Starting in February 1995, during a period of 18 months, 414 children were included- 239 in Group A and 175 in Group B. In Group A, 111 children (46.4%) had 114 viruses detected while only 5 children (2.9%) presented viruses in Group B. Respiratory Syncytial Virus was detected in 100 children from Group A (41.8%), Adenovirus in 11 (4.6%), Influenza A virus in 2 (0.8%), and Parainfluenza virus in one child (0.4%). In Group A, aerobic bacteria were found in 14 cases (5.8%). Respiratory Syncytial Virus was associated to other viruses and/or bacteria in six cases. There were two seasonal trends for Respiratory Syncytial Virus cases, which peaked in May and June. All children affected by the virus were younger than 3 years of age, mostly less than one year old. Episodic diffuse bronchial commitment and/or focal alveolar condensation were the clinical patterns more often associated to Respiratory Syncytial Virus cases. All children from Group A survived. In conclusion, it was observed that Respiratory Syncytial Virus was the most frequent pathogen found in hospitalized children admitted for severe respiratory diseases. Affected children were predominantly infants and boys presenting bronchiolitis and focal pneumonias. Similarly to what occurs in other subtropical regions, the virus outbreaks peak in the fall and their occurrence extends to the winter, which parallels an increase in hospital admissions due to respiratory diseases.


2020 ◽  
Vol 46 (1) ◽  
Author(s):  
Alberto Berardi ◽  
◽  
Tiziana Cassetti ◽  
Roberta Creti ◽  
Caterina Vocale ◽  
...  

Abstract Background Group B streptococcus (GBS) is a leading cause of sepsis, pneumonia and meningitis in infants, with long term neurodevelopmental sequelae. GBS may be associated with poor pregnancy outcomes, including spontaneous abortion, stillbirth and preterm birth. Intrapartum antibiotic prophylaxis (IAP) is currently the only way to prevent early-onset disease (presenting at 0 to 6 days of life), although it has no impact on the disease presenting over 6 days of life and its implementation is challenging in resource poor countries. A maternal vaccine against GBS could reduce all GBS manifestations as well as improve pregnancy outcomes, even in low-income countries. Main body The term “PREPARE” designates an international project aimed at developing a maternal vaccination platform to test vaccines against neonatal GBS infections by maternal immunization. It is a non-profit, multi-center, interventional and experimental study (promoted by the St George University of London. [UK]) with the aim of developing a maternal vaccination platform, determining pregnancy outcomes, and defining the extent of GBS infections in children and mothers in Africa. PREPARE also aims to estimate the protective serocorrelates against the main GBS serotypes that cause diseases in Europe and Africa and to conduct two trials on candidate GBS vaccines. PREPARE consists of 6 work packages. In four European countries (Italy, UK, Netherlands, France) the recruitment of cases and controls will start in 2020 and will end in 2022. The Italian PREPARE network includes 41 centers. The Italian network aims to collect: GBS isolates from infants with invasive disease, maternal and neonatal sera (cases); cord sera and GBS strains from colonized mothers whose infants do not develop GBS infection (controls). Short conclusion PREPARE will contribute information on protective serocorrelates against the main GBS serotypes that cause diseases in Europe and Africa. The vaccine that will be tested by the PREPARE study could be an effective strategy to prevent GBS disease.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Everlyn Kamau ◽  
James R. Otieno ◽  
Clement S. Lewa ◽  
Anthony Mwema ◽  
Nickson Murunga ◽  
...  

AbstractRespiratory syncytial virus (RSV) is recognised as a leading cause of severe acute respiratory disease and deaths among infants and vulnerable adults. Clinical RSV isolates can be divided into several known genotypes. RSV genotype BA, characterised by a 60-nucleotide duplication in the G glycoprotein gene, emerged in 1999 and quickly disseminated globally replacing other RSV group B genotypes. Continual molecular epidemiology is critical to understand the evolutionary processes maintaining the success of the BA viruses. We analysed 735 G gene sequences from samples collected from paediatric patients in Kilifi, Kenya, between 2003 and 2017. The virus population comprised of several genetically distinct variants (n = 56) co-circulating within and between epidemics. In addition, there was consistent seasonal fluctuations in relative genetic diversity. Amino acid changes increasingly accumulated over the surveillance period including two residues (N178S and Q180R) that mapped to monoclonal antibody 2D10 epitopes, as well as addition of putative N-glycosylation sequons. Further, switching and toggling of amino acids within and between epidemics was observed. On a global phylogeny, the BA viruses from different countries form geographically isolated clusters suggesting substantial localized variants. This study offers insights into longitudinal population dynamics of a globally endemic RSV genotype within a discrete location.


Vaccine ◽  
2017 ◽  
Vol 35 (32) ◽  
pp. 3951-3958 ◽  
Author(s):  
Jorge C.G. Blanco ◽  
Lioubov M. Pletneva ◽  
Raymonde O. Otoa ◽  
Mira C. Patel ◽  
Stefanie N. Vogel ◽  
...  

2015 ◽  
Vol 23 (3) ◽  
pp. 243-245 ◽  
Author(s):  
Marloes Vissers ◽  
Inge M. L. Ahout ◽  
Marien I. de Jonge ◽  
Gerben Ferwerda

ABSTRACTMaternal vaccination is currently considered a strategy against respiratory syncytial virus (RSV) infections. In RSV-infected infants, high mucosal IgG levels correlated better with reduced RSV load and lower mucosal CXCL10 levels than plasma IgG levels. For future vaccination strategies against RSV, more focus should be on the mucosal humoral immune response.


Sign in / Sign up

Export Citation Format

Share Document